InterGroup (Nasdaq:INTG) - Stock Analysis

This Simply Wall Street analysis of InterGroup (INTG) provides an overview of the company's financials, including its current market cap of US$64.2m and a share price of US$29.40. The report highlights core risks like negative shareholder equity and declining earnings. It also details recent news, performance against industry and market benchmarks, and key financial statistics from the latest earnings report.

Original reporting
Published Feb 6, 2026, 4:28 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Feb 6, 2026, 5:00 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
InterGroup (Nasdaq:INTG) - Stock Analysis — source image
Decision brief

The 30-second read

$INTGNeutralLow
01

Why it matters

These financial issues could lead to further share price decline and increased volatility, especially if negative news persists.

02

Market read

Given its small market cap and financial instability, the company's news has limited impact on broader market movements but warrants caution for investors.

03

What to watch

Potential for turnaround if management implements effective restructuring or strategic changes.

Relevance 6/10Timing: medium-term (next 1-3 months)

Background

InterGroup is a small-cap real estate company facing financial challenges, including negative shareholder equity and declining earnings.

Company-level read

Ticker impact

$INTGNeutralMedium confidence
Context

The analysis is based on recent financial data and market sentiment.

Expected impact

Potential slight decline or sideways movement in the near term, with long-term risks due to financial instability.

Evidence & confidence

Financial metrics indicate caution; however, market sentiment remains neutral, suggesting limited immediate price movement.

Market effects

The real estate management and development sector may experience minimal impact from this company's financial issues, given its small market cap and limited influence.

Limited regional impact due to the company's localized operations and small market cap.

Negligible; the company's financial health does not significantly influence global markets.

Counterpoint

Some investors may see the current low valuation as a potential bargain if the company can address its financial issues.

Key entities

  • InterGroup

    A real estate management and development firm listed on Nasdaq.

Related articles

$INTGMed

The InterGroup Corporation Reports Fiscal 2026 Results; Returns to Net Income as Hotel Operating Performance Strengthens Year-Over-Year

The InterGroup Corporation (INTG) reported fiscal 2026 results, showing a 15% revenue increase to $73.951 million and a return to net income of $0.336 million, compared to a $7.547 million loss in 2025. Hotel Operations led growth with a 43% income increase, while Real Estate and Investment segments also improved. EBITDA rose 63% to $22.834 million.

$GMABMedAI 8/10

Genmab reports phase 2 trial data for colorectal cancer drug

Genmab (NASDAQ:GMAB) reported Phase 2 trial data for petosemtamab in metastatic colorectal cancer, showing 75% and 67% response rates in first- and second-line patients, respectively. The trial involved 79 patients and was presented at the European Society for Medical Oncology Congress 2026. Genmab is conducting four Phase 3 trials and will host an investor update.

$AGENHighAI 8/10

After six weeks of treatment, 83% had little or no cancer remaining at surgery

Agenus' botensilimab and balstilimab combination therapy showed 83% of patients with locally advanced dMMR colon cancer had little or no cancer remaining at surgery. The NEOASIS study met its primary endpoint, with mild side effects reported. Agenus is exploring organ preservation in rectal cancer and advancing the approach in MSS colon cancer. The company aims to reduce treatment duration and chemotherapy use.